What we're reading, May 11, 2016: Hillary Clinton is floating the idea of letting more people buy into Medicare; American public not on board with speeding up FDA drug approvals; and Walgreens expands mental health treatment and service options.
Hillary Clinton is leaning even further to the left when it comes to healthcare. The frontrunner for the Democratic party may have attacked rival Senator Bernie Sanders for his single-payer, government-run healthcare plan, but she is now floating a similar idea, reported The Wall Street Journal. Clinton has mentioned the idea of allowing more people to buy into Medicare. Instead of limiting the plan to people age 65 years and older, she is considered letting people as young as 50 years to purchase Medicare coverage.
The FDA may be looking to speed up the approval process to get more drugs to market, but the public is not on board. According to STAT, there is strong public opposition to the federal government changing safety and effectiveness standards to allow for faster drug approvals. Only 38% were in favor of a quicker approval process, the poll from STAT and the Harvard T.H. Chan School of Public Health found. Poll respondents didn’t seem to buy the argument that reducing the time it takes for a drug to get to the market would reduce drug prices.
Walgreens Boots Alliance is expanding customer options for mental health services and treatment. Forbes reported that Walgreens will offer access to 1000 therapists and psychiatrists through telemedicine in an effort to manage mental health treatment and improve medication adherence. Walgreens is also partnering with Mental Health America to provide free screenings for conditions like depression, anxiety, and bipolar disorders.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More